Teladoc (NYSE:TDOC) CEO Jason N. Gorevic sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $48.93, for a total transaction of $1,223,250.00. Following the transaction, the chief executive officer now directly owns 636,184 shares in the company, valued at approximately $31,128,483.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of TDOC opened at $49.35 on Friday. The stock has a market capitalization of $3.08 billion, a P/E ratio of -29.91 and a beta of 0.35. Teladoc has a 12-month low of $27.30 and a 12-month high of $49.85. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.15 and a current ratio of 4.15.
Get Teladoc alerts:
Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.04. The firm had revenue of $89.64 million for the quarter, compared to analyst estimates of $86.77 million. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. Teladoc’s revenue was up 109.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) EPS. analysts expect that Teladoc will post -1.37 earnings per share for the current year.
Several research analysts have recently weighed in on TDOC shares. ValuEngine raised shares of Teladoc from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Cantor Fitzgerald reissued a “hold” rating and set a $35.00 price target (up previously from $31.00) on shares of Teladoc in a research report on Tuesday, February 27th. Deutsche Bank boosted their price target on shares of Teladoc to $45.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Canaccord Genuity boosted their price target on shares of Teladoc from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, SunTrust Banks boosted their price target on shares of Teladoc to $48.00 and gave the company a “positive” rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $42.67.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Levin Capital Strategies L.P. purchased a new stake in Teladoc in the 1st quarter valued at about $403,000. Xact Kapitalforvaltning AB raised its holdings in Teladoc by 46.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 8,530 shares of the health services provider’s stock valued at $344,000 after buying an additional 2,700 shares during the period. Royal Bank of Canada raised its holdings in Teladoc by 1,351.5% in the 1st quarter. Royal Bank of Canada now owns 64,271 shares of the health services provider’s stock valued at $2,592,000 after buying an additional 59,843 shares during the period. Millennium Management LLC purchased a new stake in Teladoc in the 1st quarter valued at about $10,906,000. Finally, Zevenbergen Capital Investments LLC raised its holdings in Teladoc by 1.8% in the 1st quarter. Zevenbergen Capital Investments LLC now owns 1,567,845 shares of the health services provider’s stock valued at $63,184,000 after buying an additional 28,205 shares during the period.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.